Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hideto Furuyama is active.

Publication


Featured researches published by Hideto Furuyama.


Journal of Nuclear Cardiology | 2003

Reduction of coronary flow reserve in areas with and without ischemia on stress perfusion imaging in patients with coronary artery disease: a study using oxygen 15–labeled water PET

Keiichiro Yoshinaga; Chietsugu Katoh; Kazuyuki Noriyasu; Yasuyoshi Iwado; Hideto Furuyama; Yoshinori Ito; Yuji Kuge; Tetsuro Kohya; Akira Kitabatake; Nagara Tamaki

BackgroundMyocardial perfusion single photon emission computed tomography (SPECT) occasionally fails to detect coronary stenosis in patients with coronary artery disease (CAD). We evaluated coronary flow reserve (CFR) using oxygen 15-labeled water in areas with and without ischemia on technetium 99m tetrofosmin stress perfusion SPECT in patients with angiographically documented CAD.Methods and ResultsTwenty-seven patients with CAD and eleven age-matched normal subjects were studied. Baseline myocardial blood flow (MBF) and MBF during hyperemia induced by intravenous adenosine triphosphate infusion (0.16 mg · kg-1 · min-1) were determined with the use of O-15-labeled water positron emission tomography, and the CFR was calculated. Tc-99m tetrofosmin stress/rest SPECT was performed for comparison. On the basis of the results of coronary angiography and SPECT, coronary segments were divided into 3 types: segments with coronary stenosis and a perfusion abnormality on stress SPECT imaging (group A, n = 16), segments with coronary stenosis without a perfusion abnormality (group B, n = 42), and remote segments with no coronary stenosis or perfusion abnormality (group C, n = 18). Baseline MBF values were similar among the 3 groups. CFR in group A was lower (1.82 ± 0.54) than in group B (2.22 ± 0.87, P < .05), in group C (2.92 ± 1.21, P < .01), and in normal segments (3.86 ± 1.24, P < .001). CFR in group B was lower than in group C (P < .02) and in normal segments (P < .001). CFR in group C was lower than in normal segments (P < .02).ConclusionsAreas with a perfusion abnormality on stress SPECT had reduced CFR. In the areas without a perfusion abnormality and with coronary stenosis, lowering of CFR was intermediate between the areas with a perfusion abnormality and remote segments. Moreover, CFR was slightly, but significantly, lower in remote segments in patients with CAD compared with normal segments.


Circulation | 2002

Assessment of Coronary Function in Children With a History of Kawasaki Disease Using 15O-Water Positron Emission Tomography

Hideto Furuyama; Yasuhisa Odagawa; Chietsugu Katoh; Yasuyoshi Iwado; Keiichiro Yoshinaga; Yoshinori Ito; Kazuyuki Noriyasu; Megumi Mabuchi; Yuji Kuge; Kunihiko Kobayashi; Nagara Tamaki

Background—Coronary abnormalities after Kawasaki disease (KD) may be associated with endothelial dysfunction due to intimal hypertrophy. The purpose of this study was to evaluate myocardial flow reserve (MFR) and endothelial function in regressed aneurysmal regions after KD. Methods and Results—Subjects were 12 patients aged 16.0±2.6 years who suffered from KD at 1.7±1.5 years and 12 normal subjects aged 26.5±3.4 years. MFR and endothelial function were estimated, respectively, by changes in myocardial blood flow (MBF) during ATP infusion and by that during cold pressor test using 15O-water positron emission tomography. Data from 24 regressed aneurysmal regions were compared with those from the corresponding regions (n=36) in the control group. Although the MBF at rest in the regressed aneurysmal regions was similar to that in controls, the MBF at a hyperemic state induced by ATP infusion in the regressed aneurysmal regions was significantly lower than that in the control regions. Therefore, the MFR in regressed aneurysmal regions was significantly lower than that in controls (3.53±0.95 versus 4.60±1.14;P <0.05). MBF at rest and during the cold pressor test did not change in the control regions, but it was significantly reduced in regressed aneurysmal regions. The ratio of MBF during the cold pressor test to MBF at rest was significantly lower in regressed aneurysmal regions than in control regions (0.67±0.15 versus 1.00±0.15;P <0.05). Conclusions—MFR and endothelial function are often impaired in regressed aneurysmal regions after KD, and tomography enables the noninvasive evaluation of coronary function.


PLOS ONE | 2017

Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients

Nobuhisa Ishiguro; Naoko Koseki; Miki Kaiho; Tadashi Ariga; Hideaki Kikuta; Takehiro Togashi; Koji Oba; Keisuke Morita; Naoko Nagano; Masanori Nakanishi; Kazuya Hara; Kyosuke Hazama; Toru Watanabe; Tatsuru Yamanaka; Satoshi Sasaki; Hideto Furuyama; Mutsuo Shibata; Satoru Shida; Akihito Ishizaka; Yuichi Tabata; Hayato Aoyagi; Hiroyuki Naito; Mikio Yoshioka; Atsuko Horino; Tsuyoshi Kenri

Objective To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia and against macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia in pediatric patients. Methods A prospective, multicenter observational study was conducted from July 2013 to August 2015. The therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin were evaluated in 59 patients with pneumonia caused by MRMP and in 50 patients with pneumonia caused by MSMP. In vitro activities of antimicrobial agents against isolates of Mycoplasma pneumoniae were also measured. Results Mean durations of fever following commencement of treatment in patients infected with MRMP and MSMP were 5.2 and 1.9 days, respectively (log-rank test, P < 0.0001). Among patients infected with MRMP, mean durations of fever were 4.6, 5.5, 1.0 and 7.5 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P < 0.0001). Among patients infected with MSMP, mean durations of fever were 2.5, 1.7, 0.9 and 4.3 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P = 0.0162). The MIC90s of azithromycin and clarithromycin among the 27 isolates of MRMP were 64 and 256 μg/ml, respectively, and those among the 23 isolates of MSMP were <0.000125 and 0.001 μg/ml, respectively. The MIC90s of minocycline and tosufloxacin among the 27 isolates of MRMP were 1.0 and 0.25 μg/ml, respectively, and those among the 23 isolates of MSMP were 1.0 and 0.5 μg/ml, respectively. Conclusion Both minocycline and tosufloxacin showed good in vitro activities against MRMP. Minocycline, but not tosufloxacin, shortened the duration of fever in pediatric patients infected with MRMP compared to the duration of fever in patients treated with macrolides.


The Journal of Pediatrics | 2003

Altered myocardial flow reserve and endothelial function late after Kawasaki disease

Hideto Furuyama; Yasuhisa Odagawa; Chietsugu Katoh; Yasuyoshi Iwado; Yoshinori Ito; Kazuyuki Noriyasu; Megumi Mabuchi; Keiichirou Yoshinaga; Yuji Kuge; Kunihiko Kobayashi; Nagara Tamaki


European Journal of Nuclear Medicine and Molecular Imaging | 2002

Decreased endothelium-dependent coronary vasomotion in healthy young smokers

Yasuyoshi Iwado; Keiichiro Yoshinaga; Hideto Furuyama; Yoshinori Ito; Kazuyuki Noriyasu; Chietsugu Katoh; Yuji Kuge; Eriko Tsukamoto; Nagara Tamaki


European Journal of Nuclear Medicine and Molecular Imaging | 2003

Estimation of myocardial blood flow and myocardial flow reserve by 99mTc-sestamibi imaging: comparison with the results of [15O]H2O PET

Yoshinori Ito; Chietsugu Katoh; Kazuyuki Noriyasu; Yuji Kuge; Hideto Furuyama; Koichi Morita; Tetsuro Kohya; Akira Kitabatake; Nagara Tamaki


The Journal of Pediatrics | 2017

Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan

Hiroshi Masuda; Tohru Kobayashi; Akira Hachiya; Yasutaka Nakashima; Hiroyuki Shimizu; Tomo Nozawa; Yoshihito Ogihara; Shuichi Ito; Shinichi Takatsuki; Nobuyuki Katsumata; Yasuo Suzuki; Satoshi Takenaka; Keiichi Hirono; Tomio Kobayashi; Hiroshi Suzuki; Eisuke Suganuma; Kei Takahashi; Tsutomu Saji; Satoshi Matsuzaki; Shoko Yamazaki; Kazuyuki Ikeda; Takuma Hara; Taichi Kanetaka; Toshitaka Kizawa; Masako Kikuchi; Ryoki Hara; Kentaro Fujii; Mayu Takahashi; Kaori Sonoda; Tomokuni Yoshihashi


Journal of Infection and Chemotherapy | 2018

Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014–2015 to 2016–2017 influenza seasons in Japan

Nobuhisa Ishiguro; Naoko Koseki; Miki Kaiho; Tadashi Ariga; Hideaki Kikuta; Koji Oba; Takehiro Togashi; Keisuke Morita; Akira Inagawa; Akiko Okamura; Shigeru Yamazaki; Satoru Shida; Mutsuko Konno; Nobuaki Kawamura; Akihito Ishizaka; Kimihiko Takada; Keiji Tsubakihara; Naoko Nagano; Mutsuo Shibata; Hideto Furuyama; Yoshihiro Matsuzono; Akemi Koike; Mari Murashita; Yoshio Hatae; Hideki Arioka; Tatsuru Yamanaka; Toru Watanabe; Yuuichi Tabata; Yoshihiro Kumita; Kyosuke Hazama


Japanese Circulation Journal-english Edition | 2002

^ O-Water Perfusable Tissue Fraction in Patients with Dilated Cardiomyopathy

Kazuyuki Noriyasu; Yoshinori Ito; Tetsuro Kohya; Akira Kitabatake; Keiichiro Yoshinaga; Hideto Furuyama; Yasuyoshi Iwado; Megumi Mabuchi; Nagara Tamaki; Chietsugu Katoh; Yuji Kuge


Japanese Circulation Journal-english Edition | 2002

Reduction of coronary flow reserve in areas with and without ischemia on SPECT : comparison with ^ Tc tetrofosmin SPECT and H_2 ^ PET

Keiichirou Yoshinaga; Yasuyoshi Iwadou; Hideto Furuyama; Nagara Tamaki; Chietsugu Katoh; Yuji Kuge; Kazuyuki Noriyasu; Yoshinori Itou; Tetsurou Kouya; Akira Kitabatake

Collaboration


Dive into the Hideto Furuyama's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge